Chronic pancreatitis is diagnosed through a combination of imaging, blood work, stool tests, and sometimes endoscopic procedures, not a single definitive test. The specific tests your doctor orders depend on how advanced the disease is, because early-stage chronic pancreatitis is notoriously difficult to detect with standard tools. Here’s what each test looks for and what it can tell you.
Why Standard Blood Tests Often Miss It
If you’ve had blood drawn and your pancreatic enzyme levels came back normal, that doesn’t rule out chronic pancreatitis. In fact, it may actually support the diagnosis in certain contexts. Serum amylase and lipase, the two enzymes doctors check to evaluate pancreatic inflammation, are reliable markers for acute pancreatitis but behave differently in the chronic form.
As chronic pancreatitis progresses, the pancreas gradually loses its ability to produce enzymes. This means amylase and lipase levels tend to drop over time rather than spike. In moderate to severe chronic pancreatitis, these levels can fall below the normal range. A study in Gut and Liver confirmed that very low lipase levels, in someone who hasn’t had pancreatic surgery, actually carry a high specificity for chronic pancreatitis. So a “normal” or low result on a standard pancreatic enzyme panel can be misleading if your doctor isn’t thinking about chronic disease.
Stool Testing for Pancreatic Function
The fecal elastase-1 test is one of the most accessible and noninvasive ways to evaluate whether your pancreas is producing enough digestive enzymes. You provide a single stool sample, which is analyzed for elastase-1, a protein the pancreas secretes that passes through the gut without being broken down. A level below 200 micrograms per gram of stool suggests the pancreas isn’t keeping up with its digestive workload.
This test performs well in moderate to severe cases, with a sensitivity around 79% and specificity of 98% when patients with acute flares are excluded. That high specificity means a positive result is very reliable. The catch is that fecal elastase-1 is less sensitive in early or mild chronic pancreatitis, when the pancreas still has enough reserve to produce near-normal enzyme levels. A normal result doesn’t guarantee your pancreas is healthy.
CT Scans and What They Reveal
A CT scan is typically the first imaging test ordered when chronic pancreatitis is suspected. It excels at picking up the hallmark signs of established disease: calcifications inside the pancreatic ducts, a shrunken (atrophied) pancreas, and a widened main pancreatic duct. Intraductal calcifications are the most specific and reliable finding on CT. When they’re present, the diagnosis is essentially confirmed.
The limitation is that CT scans are much less useful for early-stage disease. Before calcifications develop and before the duct visibly dilates, the pancreas can look relatively normal on a standard scan. If your CT comes back clean but your symptoms persist, it doesn’t mean nothing is wrong. It means the disease may be in a stage that requires more sensitive tools.
MRI and MRCP for Duct Detail
Magnetic resonance cholangiopancreatography (MRCP) provides a detailed view of the pancreatic duct system without radiation or invasive procedures. It’s particularly good at showing ductal abnormalities: a tortuous or dilated main duct, narrowing (strictures), and irregularities in the duct walls. These ductal changes are very specific signs of chronic pancreatitis on MRI.
Standard MRCP does have a blind spot: it doesn’t visualize the smaller side branches of the pancreatic duct well. A secretin-enhanced version of the test can help. After an injection of secretin, a hormone that stimulates the pancreas to release fluid, the ducts temporarily fill and become more visible. This enhanced version can also give a rough measure of how well the pancreas is functioning based on how much fluid it produces in response, making it useful for catching earlier disease that a plain MRCP might miss.
Endoscopic Ultrasound for Early Disease
Endoscopic ultrasound (EUS) is the most sensitive imaging tool for chronic pancreatitis, especially in its early stages. A thin, flexible scope with an ultrasound probe at its tip is passed through your mouth into the stomach and upper small intestine, placing the sensor just millimeters from the pancreas. This proximity gives a far more detailed picture than external imaging.
During the exam, the specialist looks for a standardized set of structural changes using what are called the Rosemont criteria. These features are grouped by importance. Major findings include bright spots with shadowing (indicating calcifications), stones in the main duct, cysts, a “honeycombing” pattern in the tissue, and an irregular duct contour. Minor findings include visible side branches, thickened duct walls, bright strands running through the tissue, and non-shadowing bright spots. A diagnosis is considered suggestive when a specific combination of major and minor features is present.
EUS is especially valuable when CT and MRCP look normal but clinical suspicion remains high. It can detect subtle texture changes in the pancreatic tissue and early duct irregularities before they become visible on other scans.
The Secretin Stimulation Test
This is the most direct way to measure how well your pancreas actually works, though it’s invasive and only available at specialized centers. After an IV injection of secretin, a thin tube collects fluid samples from your upper small intestine at 15-minute intervals over one hour. Those samples are tested for bicarbonate concentration, which reflects the pancreas’s ability to produce digestive secretions.
A peak bicarbonate level below 80 milliequivalents per liter is considered abnormal. This test can detect functional decline before structural damage shows up on imaging, making it one of the few tools that can catch early chronic pancreatitis. Its main drawbacks are limited availability, the discomfort of the endoscopic collection, and the time the procedure takes.
Ruling Out Pancreatic Cancer
Because chronic pancreatitis and pancreatic cancer can look similar on imaging and share symptoms like weight loss, pain, and digestive problems, doctors often order a blood marker called CA 19-9 to help distinguish between them. At the standard cutoff of 37 U/mL, CA 19-9 has a sensitivity of about 82% and specificity of 80% for identifying cancer over chronic pancreatitis. Patients with pancreatic cancer are roughly four times more likely to have elevated CA 19-9 than those with chronic pancreatitis alone.
However, CA 19-9 can also be elevated in chronic pancreatitis itself, particularly when there’s bile duct obstruction. And about 24% of people with pancreatic cancer have normal CA 19-9 levels. So this marker is useful as one piece of the puzzle but can’t confirm or exclude cancer on its own. If imaging shows a suspicious mass in the setting of chronic pancreatitis, a tissue biopsy (often obtained during EUS) is the definitive next step.
Genetic Testing
Genetic testing becomes relevant when chronic pancreatitis develops without an obvious cause like heavy alcohol use or gallstones, particularly in younger patients. Testing is generally recommended when someone has unexplained pancreatitis that began in childhood, recurrent acute attacks without a clear trigger, chronic pancreatitis starting before age 35 without heavy drinking (defined as more than five drinks per day), or a family history of unexplained pancreatitis.
The most well-known genetic link involves the PRSS1 gene, where specific mutations cause hereditary pancreatitis with high penetrance, meaning most people who carry the variant will develop the disease, often about a decade earlier than typical cases. Other genes that increase risk include SPINK1, CFTR (the same gene involved in cystic fibrosis, though pancreatitis-linked variants don’t always cause lung disease), CTRC, and CPA1. Some of these variants individually carry only a mild to moderate risk increase but can interact with each other or with alcohol use to significantly raise the chances of developing chronic pancreatitis.
Nutritional Testing
Chronic pancreatitis impairs fat digestion, which means your body can struggle to absorb fat-soluble vitamins: A, D, E, and K. Deficiencies in these vitamins are remarkably common even in patients whose exocrine function hasn’t completely failed. In one study of 40 patients with chronic pancreatitis, 63% were deficient in vitamin K, 53% in vitamin D, 10% in vitamin E, and 3% in vitamin A. Vitamin D and K deficiencies were the most prevalent by a wide margin.
These deficiencies have real consequences. Low vitamin D and K levels contribute to decreased bone density, and the same study found high rates of osteopenia and osteoporosis in this population. Screening for fat-soluble vitamin levels and bone density is recommended for all patients with chronic pancreatitis, not just those with obvious malabsorption symptoms like oily stools or significant weight loss.